Gregory Taylor, MD
Urology · Durango, CONPI 1932113743
Payments from drug & device makers
Across 160 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Astellas Pharma US Inc$429
- Johnson & Johnson$327
- Sumitomo Pharma America, Inc.$283
- AbbVie$189
- Pfizer$169
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,21226%
- Food & beverage$3,01965%
- Education$4099%
- Entertainment$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 20 | $1,756 |
| Astellas Pharma US Inc | 11 | $429 |
| Johnson & Johnson | 13 | $327 |
| Sumitomo Pharma America, Inc. | 14 | $283 |
| AbbVie(2 entities) | 11 | $189 |
| Pfizer | 10 | $169 |
| Urovant Sciences Inc | 10 | $164 |
| 180 Medical, Inc. | 8 | $164 |
| Endo Pharmaceuticals Inc. | 10 | $152 |
| Dendreon Pharmaceuticals LLC | 6 | $125 |
| Axonics, Inc. | 7 | $111 |
| Myovant Sciences Inc. | 6 | $99 |
| Amgen | 6 | $91 |
| Tolmar Pharmaceuticals, Inc. | 4 | $75 |
| Teleflex LLC | 1 | $71 |
| Laborie Medical Technologies Corp. | 2 | $70 |
| Tolmar, Inc. | 2 | $46 |
| Myriad Genetic Laboratories, Inc. | 3 | $38 |
| Coloplast | 2 | $38 |
| ABC Home Medical Supply, Inc. | 1 | $30 |
| Procept Biorobotics Corporation | 1 | $26 |
| Hitachi Healthcare Americas Corp. | 1 | $26 |
| Profound Medical Corp. | 1 | $23 |
| Endo USA, Inc. | 1 | $23 |
| Halozyme Inc | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Urogen Pharma, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
| Neotract Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Bayer | 1 | $11 |
| Baudax Bio Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Moses 550 D\F\L$1,212
How this compares
$4,666 in reported general payments places this provider in the 60th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 13 | $183,199 |
| MyrbetriqMirabegron | 95 | $73,521 |
| GemtesaVibegron | 33 | $27,771 |
| Abiraterone Acetate | 12 | $27,000 |
| Tamsulosin Hcl | 393 | $6,643 |
| Dutasteride | 102 | $2,617 |
| Potassium Citrate ErPotassium Citrate | 25 | $2,593 |
| Estradiol | 33 | $1,571 |
| Testosterone Cypionate | 40 | $1,217 |
| Finasteride | 75 | $1,200 |
| Solifenacin Succinate | 13 | $530 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 94 | $348 |
| Ciprofloxacin Hcl | 66 | $224 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $210 |
| CefuroximeCefuroxime Axetil | 14 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $429 | $256,720108 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $283 | $27,77133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 225 urology providers in Colorado.
Other urology in Durango
- James McBrideDurango$234K
- Sejal QuayleDurango$16K
- David CahnGolden$12.1M
- Lawrence KarshDenver$9.7M
- Alexandra RogersLafayette$541K
- Derek ZukoskyGolden$442K
- Paul MaroniAurora$234K
- James FagelsonLittleton$229K
- Damian SorceParker$224K
- Michael FerrandinoWestminster$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.